Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Importance of identifying Mycobacterium bovis as a causative agent of human tuberculosis

C. Allix-Béguec, M. Fauville-Dufaux, K. Stoffels, D. Ommeslag, K. Walravens, C. Saegerman, P. Supply
European Respiratory Journal 2010 35: 692-694; DOI: 10.1183/09031936.00137309
C. Allix-Béguec
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Fauville-Dufaux
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Stoffels
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Ommeslag
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Walravens
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Saegerman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Supply
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editors:

The case study described hereafter emphasises the potentially vital importance of Mycobacterium bovis identification for appropriate tuberculosis patient management.

M. bovis, the classical causative agent of bovine tuberculosis, can be responsible for human TB, which makes this bacterium an important zoonotic species. In developed countries, the introduction of pasteurisation, preventing contamination from milk of infected cows, and eradication programmes for infected herds have considerably reduced the prevalence of human disease due to the bovine TB bacillus, but have not completely eradicated it 1–3. Nevertheless, in many developed countries, the possibility of TB due to M. bovis infection, instead of Mycobacterium tuberculosis, is considered unlikely or even disregarded by microbiologists and clinicians.

Distinction of M. bovis from M. tuberculosis has significant relevance to patient management. In contrast to the other members of the M. tuberculosis complex, M. bovis is intrinsically resistant to pyrazinamide 4. Beyond its use for specific M. bovis identification, this natural resistance is particularly important to consider. Pyrazinamide is usually given in the classical first-line TB treatment, as it is an effective sterilising drug that helps to shorten TB therapy due to its synergistic effect with rifampicin 5. Thus, in case of M. bovis infection, pyrazinamide would be ineffective if implemented in a patient's anti-TB regimen. Unfortunately, results of in vitro susceptibility assays to pyrazinamide by conventional methods are not systematically correlated to in vivo activity. Susceptibility is, therefore, not often routinely assayed in laboratories. In addition, TB due to M. bovis is clinically, radiologically and microscopically indistinguishable from disease caused by M. tuberculosis. After culture on solid media, M. bovis displays specific characteristics like dysgonic colonies, and negative biochemical test results for nitrate reduction and niacin accumulation. However, clinical laboratories are increasingly using automated liquid culture systems followed by molecular tests for faster isolation and identification. Classical biochemical tests to identify M. bovis are not applicable using such liquid media, and most classical molecular identification methods based on targets like IS6110, 16S rDNA, 23S rDNA or ITS, do not distinguish between M. bovis and the other members of the M. tuberculosis complex. Other genetic markers 6 and the single commercial test (GenoType Mycobacterium, Hain, Nehren, Germany) allowing distinction between M. tuberculosis complex members are not widely used.

Here, we report a case of a 70-yr-old female living on a farm in Belgium. She was admitted in May 2001 with altered health condition and important weight loss, with a weight of only 32 kg. TB was diagnosed, and considered to be a reactivation of an infection contracted previously, as pulmonary lesions were already documented in 1994. At the time of hospitalisation, her sputa were strongly smear positive and the mycobacteria obtained from culture were identified as M. tuberculosis complex using a routine in-house PCR test based on IS6110 insertion sequence. Susceptibility testing for three first-line drugs (isoniazid, rifampicin and ethambutol) was performed, and isolates were susceptible to these three drugs. The patient received a classical tritherapy comprising isoniazid, rifampicin and pyrazinamide (in Belgium, ethambutol is normally prescribed only for patients originating from high TB incidence countries). She did not tolerate per os medication and received intravenous regimen. However, she developed drug hepatitis and the dosage was adjusted. Cavitary lesions on chest radiography initially enlarged during hospitalisation and sputa became negative only 6 weeks later. The patient gained 4.5 kg of weight (36.5 kg) and left the hospital with the same regimen of antituberculous drugs, two months after her admission.

5 months later, in December 2001, the patient, who was still on standard isoniazid and rifampicin follow-up regimen, was readmitted with increasing cough and dyspnoea, and a weight of 34.5 kg. There was wheezing on both lungs with a sort of lapping at the upper left lung lobe. Thorax radiography showed that this lobe was largely damaged and replaced by a large cavity. Although culture was negative after 4 weeks, sputum was smear positive.

During this second admission, transaminases suddenly increased, and gastroenterology examination suggested a novel episode of isoniazid-related hepatitis. This sudden recurrence of hepatitis was thought to result from lack of compliance of the patient at home and restored adherence to her anti-TB treatment after readmission. Therefore, isoniazid was replaced by pyrazinamide in addition to ethambutol in the follow-up regimen. The patient left the hospital after 3 weeks. She died from respiratory insufficiency 2 months later.

The mycobacterial strain infecting this patient was subsequently identified as M. bovis, independently from the above clinical history as follows. In 2002, the veterinary inspection service detected TB lesions on a cow at the slaughterhouse and subsequently a TB outbreak in cattle due to M. bovis on a farm. Epidemiological inquiry mentioned a case of human TB in the farmer's family, namely the patient described above. Consequently, the veterinary public health service alerted the medical public health service. Mycobacterial interspersed repetitive unit variable-number tandem repeat (MIRU-VNTR) typing based on 28 loci 7, 8, spoligotyping 9 and IS6110 restriction fragment length polymorphism 10 typing concordantly revealed fully matching genotypes for human and bovine isolates and disclosed, at the same time, the M. bovis identification of the patient's isolate (fig. 1⇓) 11.

Fig. 1—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1—

Mycobacterium bovis strain genotypes and identification. a) Comparison of human (above) and bovine (below) isolate genotypes. b) M. bovis identification based on MIRU-VNTRplus best match analysis. Grey-shaded boxes indicate variant mycobacterial interspersed repetitive unit variable-number tandem repeat (MIRU-VNTR) alleles between the human isolate and an M. bovis reference strain. Please note that identification in MIRU-VNTRplus is based on the set of 24 MIRU-VNTR loci standardised for Mycobacterium tuberculosis 8, 11. According to standardisation, MIRU-VNTR markers are designated by their position in kbp on the M. tuberculosis H37Rv chromosome. RFLP: restriction fragment length polymorphism.

The two M. bovis isolates displayed a rare four-IS6110 band fingerprint observed in only 3% of Belgian herds 7. This observation rendered even more likely the conclusion that both isolates represented infection by the same M. bovis strain, based on the concordant results of the three genotyping techniques. Although the genotype identity of the human and bovine isolates does suggest zoonotic infection acquired on this farm, a definitive scenario for the transmission route could not be established. No culture was available to confirm the patient's suspected previous TB episode dating back to 1994, and thus to confirm or exclude subsequent reactivation of such infection. Moreover, retrospective investigation of available veterinary inspection data did not allow us to establish when the TB outbreak precisely started in this herd.

Regardless and more importantly, the initial absence of M. bovis identification of this patient's isolate compromised the efficiency of her treatments, and plausibly influenced the final fatal outcome. Because of this lack of specific identification, pyrazinamide was inadequately administered in the 2 months of induction chemotherapy and, worst, was inappropriately used to replace isoniazid in the follow-up treatment because of toxic hepatitis.

If the pneumologist had initially known that M. bovis was the causative agent, a treatment with isoniazid, rifampicin, and ethambutol, instead of pyrazinamide, would probably have been started. For the second episode, the pneumologist would probably have added a quinolone, again instead of pyrazinamide, in addition to ethambutol and rifampicin. In this context, nonutilisation of pyrazinamide would additionally have avoided hepatotoxic effects also known to be associated with this drug, for a patient prone to anti-TB drug-related hepatitis.

In conclusion, our report shows that absence of specific identification of M. bovis may have adverse consequences for TB patient management. We believe that even in high-income countries, human TB due to M. bovis is underestimated, because of frequent use of identification techniques that do not specifically distinguish M. bovis from the rest of the M. tuberculosis complex, and because susceptibility to pyrazinamide is not systematically tested. Therefore, clinical laboratories should routinely use molecular tests to differentiate M. bovis from M. tuberculosis and/or systematically check resistance to pyrazinamide. In addition, our report constitutes an additional example of the persistent significance of M. bovis as a zoonotic pathogen 1, 2, even in countries such as Belgium, which has been declared officially free of cattle TB according to the European Commission decision 2003/467/EC. Finally, it illustrates that molecular-guided cooperation between human and veterinary health services can improve detection of zoonoses.

Support statement

C. Allix-Béguec was a fellow of the Brussels-Capital Region, Belgium and P. Supply is a researcher of the Centre National de la Recherche Scientifique (CNRS, Lille, France).

Statement of interest

None declared.

Acknowledgments

P. Sonck (Institut Scientifique de Santé Publique, Direction maladies transmissibles et infectieuses, ex Institut Pasteur, Brussels, Belgium) is gratefully acknowledged for expertise in IS6110 restriction fragment length polymorphism analysis.

    • © ERS Journals Ltd

    References

    1. ↵
      Evans JT, Smith EG, Banerjee A, et al. Cluster of human tuberculosis caused by Mycobacterium bovis: evidence for person-to-person transmission in the UK. Lancet 2007;369:1270–1276.
      OpenUrlCrossRefPubMedWeb of Science
    2. ↵
      LoBue PA, Moser KS. Treatment of Mycobacterium bovis infected tuberculosis patients: San Diego County, California, United States, 1994-2003. Int J Tuberc Lung Dis 2005;9:333–338.
      OpenUrlPubMedWeb of Science
    3. ↵
      Rivero A, Marquez M, Santos J, et al. High rate of tuberculosis reinfection during a nosocomial outbreak of multidrug-resistant tuberculosis caused by Mycobacterium bovis strain B. Clin Infect Dis 2001;32:159–161.
      OpenUrlAbstract/FREE Full Text
    4. ↵
      O'Donohue WJ Jr, Bedi S, Bittner MJ, et al. Short-course chemotherapy for pulmonary infection due to Mycobacterium bovis. Arch Intern Med 1985;145:703–705.
      OpenUrlCrossRefPubMedWeb of Science
    5. ↵
      Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603–662.
      OpenUrlCrossRefPubMedWeb of Science
    6. ↵
      Brosch R, Gordon SV, Marmiesse M, et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA 2002;99:3684–3689.
      OpenUrlAbstract/FREE Full Text
    7. ↵
      Allix C, Walravens K, Saegerman C, et al. Evaluation of the epidemiological relevance of variable-number tandem-repeat genotyping of Mycobacterium bovis and comparison of the method with IS6110 restriction fragment length polymorphism analysis and spoligotyping. J Clin Microbiol 2006;44:1951–1962.
      OpenUrlAbstract/FREE Full Text
    8. ↵
      Supply P, Allix C, Lesjean S, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 2006;44:4498–4510.
      OpenUrlAbstract/FREE Full Text
    9. ↵
      Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997;35:907–914.
      OpenUrlAbstract/FREE Full Text
    10. ↵
      van Embden JD, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol 1993;31:406–409.
      OpenUrlAbstract/FREE Full Text
    11. ↵
      Allix-Beguec C, Harmsen D, Weniger T, et al. Evaluation and strategy for use of MIRU-VNTRplus, a multifunctional database for online analysis of genotyping data and phylogenetic identification of Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2008;46:2692–2699.
      OpenUrlAbstract/FREE Full Text
    View Abstract
    PreviousNext
    Back to top
    View this article with LENS
    Vol 35 Issue 3 Table of Contents
    European Respiratory Journal: 35 (3)
    • Table of Contents
    • Table of Contents (PDF)
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Importance of identifying Mycobacterium bovis as a causative agent of human tuberculosis
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    Importance of identifying Mycobacterium bovis as a causative agent of human tuberculosis
    C. Allix-Béguec, M. Fauville-Dufaux, K. Stoffels, D. Ommeslag, K. Walravens, C. Saegerman, P. Supply
    European Respiratory Journal Mar 2010, 35 (3) 692-694; DOI: 10.1183/09031936.00137309

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    Importance of identifying Mycobacterium bovis as a causative agent of human tuberculosis
    C. Allix-Béguec, M. Fauville-Dufaux, K. Stoffels, D. Ommeslag, K. Walravens, C. Saegerman, P. Supply
    European Respiratory Journal Mar 2010, 35 (3) 692-694; DOI: 10.1183/09031936.00137309
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Support statement
      • Statement of interest
      • Acknowledgments
      • References
    • Figures & Data
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Fibrosis in dyskeratosis congenita with TINF2 mutation
    • Pneumomediastinum and dehydration in cystic fibrosis
    • How can we achieve better prevention of TB among contacts?
    Show more Letters

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2023 by the European Respiratory Society